Navigation Links
Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study.  The propriety formulation was designed and manufactured at Particle Sciences.  In the Phase 1 clinical trial NRL-1 demonstrated a pharmacokinetic profile comparable to that reported in the literature for Diastat® (rectal diazepam gel), the only FDA approved therapeutic product for home treatment of acute repetitive seizures.  The bioavailability of the NRL-1 intranasal formulation was 96%.

According to Dr. Robert Lee, Particle Sciences VP of Pharmaceutical Development, "We are obviously very pleased with the results Neurelis have obtained.  It has been a pleasure working with them and very rewarding to contribute to a product that should truly improve the quality of life for patients with acute repetitive seizures and their caregivers.  We were able to achieve extremely high levels of solubilized diazepam using our DOSE® platform that combines empirically obtained data with customized solubility software.  This approach along with Particle Sciences' cGMP analytical and manufacturing services have enabled our clients to more rapidly advance to the clinic with commercially viable formulations."

David F. Hale, Chairman of Neurelis, said that "The team at Neurelis was very pleased with the work on the formulation conducted by Particle Sciences.  They really focused on a key issue with diazepam which is solubility and developed two proprietary formulations which we evaluated in the clinical trial.  Based on the results obtained in the clinical trial we plan to move ahead with the further development of this product candidate for patients with epilepsy who have acute repetitive seizures."

Particle Sciences Inc. is an integrated provider of drug development services.  Particle Sciences utilizes a broad suite of drug delivery technologies to address a diverse range of challenges.  With special expertise in solubility, particulate based formulations and drug/device combination products, Particle Sciences has become a leader in drug delivery development.  Through a full range of formulation, analytic, bioanalytic, and sterile and non-sterile manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit, email or contact us at (610) 861-4701 for information.

Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market.  Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.

Contact: Maureen Cochran

SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
2. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
3. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
4. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
5. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
6. Particle Sciences Expands Its Combination Product Capabilities
7. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
8. Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities
9. MicroConstants Now Offers Nanoparticle Formulation Services
10. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
11. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):